News | May 07, 2021
Lonza announces expansion plans for mammalian manufacturing facilities
The facility is expected to be completed in 2024
The facility is expected to be completed in 2024
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.
Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde, executive vice president, Thermo Fisher.
Subscribe To Our Newsletter & Stay Updated
